Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model

Matthew Dent, Krystal Hamorsky, Thibaut Vausselin, Jean Dubuisson, Yoshinari Miyata, Yoshio Morikawa, Nobuyuki Matoba

To cite this version:
Matthew Dent, Krystal Hamorsky, Thibaut Vausselin, Jean Dubuisson, Yoshinari Miyata, et al.. Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model. Cellular and Molecular Gastroenterology and Hepatology, Philadelphia, PA: American Gastroenterological Association, [2015]-, 2020, 10.1016/j.jcmgh.2020.08.009. hal-02992405

HAL Id: hal-02992405
https://hal.archives-ouvertes.fr/hal-02992405
Submitted on 6 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model

Matthew Dent,1 Krystal Hamorsky,2,3,4 Thibaut Vausselin,5 Jean Dubuisson,5 Yoshinari Miyata,6 Yoshio Morikawa,6 and Nobuyuki Matoba1,3,4

1Department of Pharmacology and Toxicology, 2Department of Medicine, 3James Graham Brown Cancer Center, 4Center for Predictive Medicine, University of Louisville School of Medicine, Louisville, Kentucky; 5University of Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019, UMR 8204, Center for Infection and Immunity of Lille, Lille, France; 6PhoenixBio USA Corporation, New York, New York

SUMMARY

Hepatitis C virus (HCV) infection remains a major cause of end-stage liver disease. Here, we show the efficacy and safety of a novel biotherapeutic targeting a HCV glyco-biomarker in a mouse model, providing a foundation for a new anti-HCV strategy.

BACKGROUND & AIMS: Infection with hepatitis C virus (HCV) remains a major cause of morbidity and mortality worldwide despite the recent advent of highly effective direct-acting antivirals. The envelope glycoproteins of HCV are heavily glycosylated with a high proportion of high-mannose glycans (HMGs), which serve as a shield against neutralizing antibodies and assist in the interaction with cell-entry receptors. However, there is no approved therapeutic targeting this potentially druggable biomarker.

METHODS: The anti-HCV activity of Avaren-Fc (AvFc) was evaluated through the use of in vitro neutralization assays as well as an in vivo challenge in the PXB chimeric human liver mouse model. Drug toxicity was assessed by histopathology, serum alanine aminotransferase, and mouse body weights.

RESULTS: AvFc was capable of neutralizing cell culture-derived HCV in a genotype-independent manner, with 50% inhibitory concentration values in the low nanomolar range. Systemic administration of AvFc in a histidine-based buffer was well tolerated; after 11 doses every other day at 25 mg/kg there were no significant changes in body or liver weights or in blood human albumin or serum alanine aminotransferase activity. Gross necropsy and liver pathology confirmed the lack of toxicity. This regimen successfully prevented genotype 1a HCV infection in all animals, although an AvFc mutant lacking HMG binding activity failed.

CONCLUSIONS: These results suggest that targeting envelope HMGs is a promising therapeutic approach against HCV infection, and AvFc may provide a safe and efficacious means to prevent recurrent infection upon liver transplantation in HCV-related end-stage liver disease patients. (Cell Mol Gastroenterol Hepatol 2020;--:--:-- https://doi.org/10.1016/j.jcmgh.2020.08.009)

Keywords: Hepatitis C Virus; Entry Inhibitor; Plant-Made Pharmaceutical; High-Mannose Glycan; Antiviral Therapy.

Hepatitis C virus (HCV) is an enveloped monopartite positive-sense single-strand RNA virus in the family Flaviviridae and the causative agent of hepatitis C disease. Its genome encodes 3 structural (core, E1, E2) and 7 nonstructural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A,
and NSSB). HCV is highly heterogenous and distributed globally, consisting of 7 genotypes, each subdivided further into multiple subtypes. Genotypes 1 and 2 are the predominant genotypes worldwide and are particularly concentrated in high-income and upper-middle-income countries, whereas genotypes 3 and 4 are more common in lower-middle and low-income countries. In the United States, injection drug use represents the primary risk factor for contracting HCV infection. Approximately 15%–25% of people acutely infected with HCV will clear the virus, while the remainder will develop chronic infection that can persist largely unnoticed for decades. Indeed, many HCV carriers discover their chronic infection after they have developed cirrhosis. Chronic HCV infection also is associated with the development of hepatocellular carcinoma, and patients with the disease are more likely to develop cryoglobulinemia and non-Hodgkin’s lymphoma.

There is no vaccine currently available for HCV. Before 2011, the standard chronic HCV treatment was a nonspecific antiviral medication using ribavirin combined with pegylated interferon-α, which was associated with significant toxicity and limited treatment efficacy. In 2011, the US Food and Drug Administration approved the first-generation of direct-acting antivirals (DAAs) for HCV: boceprevir and telaprevir, both of which inhibit the viral protease (NS3/4A), but required co-treatment with ribavirin and peginterferon. Further approval of more potent DAAs, such as NS3/4A, NS5B, and NSSB, inhibitors, led to the development of oral ribavirin/peginterferon-free regimens. Multi-DAAR regimens achieve sustained virologic response (defined as a period of time with no viral RNA detection) rates as high as 100%, and are less toxic and more tolerable than their predecessors. Although the cure rates are remarkable, populations of patients exist who may not benefit from DAA therapy, especially patients with compensated cirrhosis resulting from chronic HCV infection, for whom liver transplantation may be a last resort. Moreover, recurrent infection occurs universally and rapidly after liver transplantation, which increases the risk of accelerated cirrhosis, graft failure, and death. DAAs, by their nature, cannot prevent recurrent infection. Therefore, alternative or complementary therapies to DAAs that can block viral entry to target cells, such as antibodies or other molecules acting alike, may need to be considered in these circumstances. However, there is currently no entry inhibitor approved for HCV treatment.

The HCV envelope proteins E1 and E2 are heavily glycosylated and, similar to glycoproteins of other enveloped viruses (eg, human immunodeficiency virus [HIV] and the coronaviruses), have a high proportion of high-mannose-type N-glycans (HMGs) on their surface. These glycans typically are processed to hybrid and complex forms on glycoproteins secreted by healthy cells. Thus, the HMGs on the surface of HCV may be considered a druggable target. We previously described the development of an HMG-targeting lectin-Fc fusion protein, or lectibody, called Avaren-Fc (AvFc), which was shown to bind with high affinity to clusters of HMGs on the HIV envelope protein glycoprotein (gp)120 and effectively neutralize multiple HIV clades and groups including HIV-2 and simian immunodeficiency virus. Further analysis indicated that AvFc can bind to HCV E2 protein. Therefore, in this study, we aim to investigate the anti-HCV therapeutic potential of AvFc in vitro neutralization assays and an in vivo HCV challenge study using PXB mice, a chimeric urokinase plasminogen activator/severe combined immunodeficiency (uPA/SCID) mouse model transplanted with human hepatocytes (reviewed by Tanoto and Kojima).

Results
AvFc Shows Broad Anti-HCV Activity In Vitro
Building on our previous observation that AvFc has affinity to a recombinant HCV E2 envelope protein, we first examined whether AvFc inhibits HCV infection in vitro using multiple genotypes of cell culture-produced virus (HCVcc) or pseudotyped virus (HCVpp). AvFc significantly blocked the infection of the human liver cell line HuH-7 by HCVcc, from genotypes 1a, 2a, 4a, 5a, and 6a, with 50% inhibitory concentration values in the low nanomolar range (Table 1 and Figure 1A). Compared with Avaren monomer, AvFc overall showed approximately 2-log higher activity, although no inhibitory effect was observed for the plant-produced anti-HIV broadly neutralizing antibody VRC01, which shares the same human IgG1 Fc region with AvFc. In addition, Avaren and AvFc, but not VRC01, effectively neutralized HCVpp harboring a murine leukemia virus backbone, suggesting that the lectin and the lectibody act as an entry inhibitor (Figure 1B).

Formulation of AvFc Into a Biocompatible Buffer for In Vivo Studies
Previously, we found that AvFc has limited solubility in phosphate-buffered saline (PBS) at concentrations greater than 1 mg/mL (unpublished observation). To facilitate in vivo studies, we screened for an optimal liquid formulation for systemic administration that can impart improved stability and solubility to AvFc at higher concentrations. Initial buffer screening showed that AvFc is prone to degradation at and below a pH of 6.5, suggesting that AvFc is not stable in acidic pH conditions (Figure 2, Table 2). Further preformulation studies led us to identify an optimal buffer composed of 30 mmol/L histidine, pH 7.0, 100 mmol/L sucrose, and 100 mmol/L NaCl. Although AvFc showed comparable melting temperature in the histidine buffer and PBS in differential scanning fluorimetry (62.49°C ± 0.13°C).

Abbreviations used in this paper: ALT, alanine aminotransferase; AvFc, Avaren-Fc; DAA, direct-acting antiviral; H-Ab, human antibody; HCV, hepatitis C virus; HCVcc, cell-culture-derived hepatitis C virus; HCVpp, hepatitis C virus pseudovirus; HIV, human immunodeficiency virus; HMG, high-mannose glycans; JFH, 1; PBS, phosphate-buffered saline; RT-PCR, reverse-transcription polymerase chain reaction; uPA/SCID, urokinase plasminogen activator/severe combined immunodeficiency.

© 2020 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1. IC₅₀ Values for AvFc and Avaren Against HCVcc

| Virus       | Genotype | Avaren IC₅₀, nmol/L | AvFc IC₅₀, nmol/L |
|-------------|----------|---------------------|-----------------|
| JFH1/H77    | 1a       | 529.28 ± 158.78     | 1.69 ± 0.39     |
| JFH1        | 2a       | 484.62 ± 109.16     | 1.69 ± 0.78     |
| JFH1/ED43   | 4a       | 204.27 ± 1.65       | 2.85 ± 0.91     |
| JFH1/SA13   | 5a       | 148.86 ± 2.48       | 2.33 ± 0.13     |
| JFH1/HK6a   | 6a       | 114.95 ± 52.93      | 1.95 ± 0.78     |
| Average     |          | 269.39 ± 65.00      | 2.10 ± 0.60     |

IC₅₀, 50% inhibitory concentration.

vs 62.68°C ± 0.25°C (Figure 3A), sodium dodecyl sulfate–polyacrylamide gel electrophoresis analysis showed that the lectibody holds superior stability in the histidine buffer upon accelerated stability testing via overnight incubation at 55°C (Figure 3B). When concentrated to approximately 10 mg/mL, AvFc remained stable in solution in the histidine buffer over 72 hours at 4°C and room temperature, while showed a significant concentration decrease concomitant with increasing turbidity in PBS (Figure 3C), further showing the histidine buffer’s superiority for AvFc formulation.

**Pharmacologic and Toxicologic Analysis of AvFc in Mice**

To determine an optimal dosing regimen for an HCV challenge experiment, a pharmacokinetic analysis of AvFc was conducted in C57bl/6 mice. After a single intraperitoneal injection of AvFc at a dose of 25 mg/kg, a peak drug concentration was observed between 2 and 4 hours, with a half-life of 24.5 hours in male animals and 18.5 hours in female animals (Figure 4). After 48 hours, in both male and female animals, the plasma concentration of AvFc remained above a target trough concentration of 130 nmol/L (10 μg/mL), at which time AvFc showed more than 90% neutralization effects against HCV (Figure 1). Consequently, these results suggested that administration of the drug every other day might be sufficient to keep the virus under control in a murine HCV challenge model.

We then assessed the safety of every-other-day administration of AvFc in PXB mice. To effectively discern potential toxicity associated with AvFc HMG-binding activity, we included an AvFc variant lacking HMG-binding activity as a control (AvFcHMG) (Figure 5A and B). PXB mice received either the vehicle (the histidine buffer described earlier) every other day for 11 total doses, AvFc at 25 mg/kg every

---

**Figure 1. In vitro HCV inhibition assays.** (A) Avaren and AvFc inhibit cell–culture derived HCV. The JFH1 virus was preincubated with Avaren, AvFc, or the control antibody VRC01 for 30 minutes at 37°C before incubation with Huh-7 cells. At 48 hours after infection, infected cells were quantified by indirect immunofluorescence with an HCV-specific antibody. Results are expressed as a percentage of infection compared with a control infection in the absence of compound. Error bars indicate SEM values from at least 3 independent experiments. (B) Avaren and AvFc inhibit HCV entry. Retroviral pseudotypes bearing HCV envelope glycoproteins of the JFH1 virus (HCVpp) were preincubated with Avaren, AvFc, or the control antibody VRC01 for 30 minutes at 37°C before incubation with Huh-7 cells. At 48 hours after infection, cells were lysed to quantify the luciferase activity. Results are expressed as the percentage of infection compared with the control infection in the absence of compound. Error bars indicate SEM values from at least 3 independent experiments.
other day for a total of 8 or 11 doses, or AvFc\textsuperscript{lec} at 25 mg/kg every other day for 11 total doses. As shown in Figure 6A–C, no significant differences in either body weights, blood hAlb levels, or serum alanine aminotransferase (ALT) activity were observed. In addition, no significant differences in relative liver weight were seen (Figure 6D). These results indicate that AvFc, formulated in the histidine buffer, was well tolerated in the immunocompromised mice engrafted with human hepatocytes.

Histopathology was performed to evaluate any potential toxicity to the human liver grafts resulting from AvFc administration (Table 3 and Figure 7). In the human hepatocyte area, a slight to moderate (scores of 2–3 in Table 2) macrovesicular fatty change, a characteristic change of human hepatocytes in the PXB mouse, was observed in all mice, including the vehicle-treated group (Figure 7A–C). Minimal inflammatory cell infiltration around vacuolated hepatocytes (score, 1) was seen in 1 mouse each from the 11-dose AvFc and AvFc\textsuperscript{lec} groups (Figure 7D and E); however, this was unlikely treatment-related because a similar change is seen occasionally in PXB mice (PhoenixBio, New York, NY) (unpublished observation). No AvFc treatment-specific change was observed, except for an incidental build-up of pigmentation found in the Glisson’s sheath in the liver of 1 mouse (Figure 7F). Collectively, it was concluded that there was no treatment-related adverse effect in the liver tissue. The full pathology report may be found in the Supplementary Information.

Table 2. Buffers Used in the Initial Screening of AvFc Preformulation Analysis

| Number | Formulation | pH |
|--------|-------------|----|
| 1      | 30 mmol/L glutamate (5.61 g/L NaOOCCH\textsubscript{2}CH\textsubscript{2}CH(NH\textsubscript{2})COOH × H\textsubscript{2}O)\textsuperscript{a} | 4.5 |
| 2      | 30 mmol/L glutamate (5.61 g/L NaOOCCH\textsubscript{2}CH\textsubscript{2}CH(NH\textsubscript{2})COOH × H\textsubscript{2}O)\textsuperscript{a} | 5.0 |
| 3      | 30 mmol/L acetate (2.46 g/L CH\textsubscript{3}COONa)\textsuperscript{a} | 4.5 |
| 4      | 30 mmol/L acetate (2.46 g/L CH\textsubscript{3}COONa)\textsuperscript{a} | 5.0 |
| 5      | 30 mmol/L citrate (350 mL 0.1 mol/L C\textsubscript{6}H\textsubscript{5}O\textsubscript{7}Na\textsubscript{3} × 2 H\textsubscript{2}O) | 5.0 |
| 6      | 30 mmol/L citrate (115 mL 0.1 mol/L C\textsubscript{6}H\textsubscript{5}O\textsubscript{7}Na\textsubscript{3} × 2 H\textsubscript{2}O) | 6.0 |
| 7      | 30 mmol/L succinate (4.86 g/L NaOOCCH\textsubscript{2}CH\textsubscript{2}COONa)a | 5.5 |
| 8      | 30 mmol/L succinate (4.86 g/L NaOOCCH\textsubscript{2}CH\textsubscript{2}COONa)a | 6.5 |
| 9      | 30 mmol/L histidine (4.65 g/L C\textsubscript{6}H\textsubscript{5}N\textsubscript{2}O\textsubscript{2})\textsuperscript{a} | 6.0 |
| 10     | 30 mmol/L histidine (4.65 g/L C\textsubscript{6}H\textsubscript{5}N\textsubscript{2}O\textsubscript{2})\textsuperscript{a} | 7.0 |
| 11     | 30 mmol/L phosphate (2.89 g/L Na\textsubscript{2}H\textsubscript{2}PO\textsubscript{4} × H\textsubscript{2}O, 2.42 g Na\textsubscript{2}HPO\textsubscript{4} × 7 H\textsubscript{2}O) | 6.5 |
| 12     | 30 mmol/L phosphate (1.75 g/L Na\textsubscript{2}H\textsubscript{2}PO\textsubscript{4} × H\textsubscript{2}O, 4.64 g Na\textsubscript{2}HPO\textsubscript{4} × 7 H\textsubscript{2}O) | 7.0 |
| 13     | 30 mmol/L phosphate (0.78 g/L Na\textsubscript{2}H\textsubscript{2}PO\textsubscript{4} × H\textsubscript{2}O, 6.53 g Na\textsubscript{2}HPO\textsubscript{4} × 7 H\textsubscript{2}O) | 7.5 |
| 14     | 30 mmol/L Tris (3.63 g/L NH\textsubscript{2}C(CH\textsubscript{2}OH)\textsubscript{3})\textsuperscript{a} | 7.5 |
| 15     | PBS (0.144 g/L K\textsubscript{2}H\textsubscript{2}PO\textsubscript{4}, 9 g/L NaCl, 0.795 g/L Na\textsubscript{2}HPO\textsubscript{4}) | 7.2 |

\textsuperscript{a}pH was adjusted with 1 mol/L NaOH or 1 mol/L HCl.
AvFc Protects Against HCV Infection In Vivo

Lastly, we assessed the protective efficacy of AvFc against HCV infection in vivo using the treatment regimen described earlier. PXB mice were inoculated intraperitoneally with a genotype 1a virus along with initial treatment with 25 mg/kg of AvFc or AvFclec on day 0. As shown in Figure 8A, AvFclec-treated mice showed high serum HCV RNA levels from day 7 after challenge through the end of the study on day 35. In sharp contrast, animals treated with both 8 and 11 doses of AvFc did not show any quantifiable level ($4.0 \times 10^4$ copies/mL) of HCV RNA in sera, indicating that the lectibody prevented the infection of human liver grafts by the virus. Similar to the results in Figure 3, overall no major toxicity signal was noted in body weights, human albumin (h-Alb), or h-ALT levels between the test groups, although there was a temporal decrease in body weight and h-Alb in 1 of the AvFc-treated groups at an early time point, indicating that the liver grafts remained functional over the course of the study (Figure 8B–D).

Discussion

In this study we showed that the HMG-binding lectibody AvFc shows broad genotype-independent anti-HCV activity. In addition, systemic administration of AvFc effectively protected chimeric human-mouse liver mice from infection with a genotype 1a virus without apparent toxicity, providing in vivo proof-of-concept for the lectibody's antiviral potential.

The mechanism of HCV neutralization by AvFc likely is through binding to HMGs on the E1/E2 envelope protein dimer, which blocks their interaction with host cell...
receptors and viral entry. Unlike HIV envelope glycoproteins, whose glycan content can vary widely between strains, the number and position of glycosylation sites on E1/E2 are highly conserved, indicating their critical role in HCV’s infectious processes. The notion that AvFc functions as an entry inhibitor is supported by the fact that the lectobody has affinity to the E2 protein and that other mannose-binding lectins, such as Griffithsin or Cyanovirin-N, inhibit entry in this manner. AvFc inhibited multiple genotypes of HCV with average 50% inhibitory concentrations more than 100-fold lower than that of the nonmer Avaren lectin (Table 1), indicating that the multivalent recognition of HMGs on the surface of the virus, brought about by the dimerization of Avaren via Fc fusion, led to greater entry inhibition. Unlike other antiviral lectins, however, the inclusion of the human IgG1 Fc region implicates the possibility of Fc-mediated effector functions, such as antibody-dependent cell-mediated cytotoxicity, against infected cells. In fact, Fc-mediated effector functions greatly contributed to the antiviral potency of AvFc against HIV, as determined by a primary cell-based inhibition assay and an antibody-dependent cell-mediated viral infection assay. Accordingly, the remarkable efficacy seen in the present in vivo HCV challenge study may be partially Fc-mediated. Further investigations are necessary to address this possibility.

The present study also showed that AvFc therapy is well tolerated in mice and human hepatocytes because every-other-day intraperitoneal administration of 25 mg/kg AvFc, of up to 11 doses, did not show any obvious toxicity in PXB mice by gross necropsy or histopathology of engrafted human hepatocytes, and it did not result in significant changes in body weight, h-Alb level, or ALT level (Figures 6 and 7). This corroborates our previous observation that AvFc administration, both intraperitoneally and intravenously, was well tolerated and produced no toxicity in mice, rats, or rhesus macaques. We hypothesize that the lack of any significant toxicity is attributable to the unique HMG-binding mechanism of AvFc, whereby it requires multivalent interaction with several HMGs in proximity to show high-affinity binding to a glycoprotein target. In line with this hypothesis, Hoque et al. showed that the 3 binding pockets of the parent lectin actinohivin can bind up to 3 independent HMGs, providing high-affinity binding when the HMGs are in relatively close proximity. This implies that AvFc may not interact effectively with healthy normal cells and tissues that do not usually show clusters of HMGs on their surfaces. In contrast, glycoproteins of many enveloped viruses show a high proportion of these immature forms of N-glycans. Although HCV E2 has fewer N-glycosylation sites (approximately 11) than the HIV gp120 (which has between 20 and 30, depending on the strain), E2 likely is present on the surface of HCV at a higher density and thus provides higher local concentrations of HMGs. Further studies are necessary to show a threshold HMG concentration that enables efficient interaction between AvFc and the surfaces of cells or viruses.

Although alcoholic liver disease has now surpassed HCV infection as the number one indication for liver transplantation in the United States, a large number of procedures will continue to be performed for the foreseeable future in patients with HCV-related decompensated cirrhosis. A major outstanding issue is the lack of effective treatment protecting the allograft liver from recurrent infection by the virus that remained circulating in the periphery at the time of transplant. As a consequence, re-infection of donor livers occurs universally, as early as in the first 90 minutes of reperfusion, and can result in accelerated fibrosis and increased risk of graft failure, cirrhosis, and hepatocellular carcinoma. In fact, allograft failure resulting from re-infection is the leading cause of secondary transplants and death in HCV-infected patients who have received a liver transplant. Patients cured of HCV with DAAs after liver transplantation still have a higher-than-normal risk of hepatocellular carcinoma, and the high cost of the drugs represents a significant barrier to their widespread use. Furthermore, emergent drug resistance, even in DAA combination therapies, although rare, represents a particular challenge for further treatment. Unlike DAAs, entry inhibitors neutralize circulating viruses and physically block the viral infection of target cells. The use of entry inhibitors peripherally upon liver transplantation, either alone or in combination with DAAs, may improve treatment outcomes significantly. Thus, although the effectiveness of DAAs is not in question, there still are unmet needs that may be addressed through the use of entry inhibitors.

To date, no entry inhibitor has been approved for the treatment or prevention of HCV. Two major drug candidates, Civacir and MBL-HCV1, have shown some promise in clinical trials (NCT01804829 and NCT01532908). Although larger studies are needed, it appears that entry...
inhibitors in combination with DAAs may represent a new treatment paradigm for HCV patients receiving a liver transplant. Despite both MBL-HCV1 and Civacir being capable of neutralizing a broad range of HCV genotypes, viral resistance still can develop through mutations in the envelope proteins E1/E2, in particular through shifting glycan positions.40,41 In this regard, AvFc in its own right could be less susceptible to amino acid mutations because it targets the glycan shield of the virus rather than a specific epitope. Deletions of glycans, even if occurring after prolonged exposure to a carbohydrate-binding agent such as AvFc, may result in a significant decrease in viral fitness by decreasing E1/E2 incorporation into HCV particles or increased susceptibility to humoral immunity resulting from a breach in the glycan shield.27,42 Our results provide a foundation to test the earlier-described hypotheses and feasibility of the HMG-targeting anti-HCV strategy. Of note, a unique advantage of AvFc over the 2 antibody-based entry inhibitor candidates described earlier is that the lectibody has the capacity to neutralize both HIV24 and HCV (present study). Accordingly, AvFc may provide an effective means (eg, pre-exposure prophylaxis) to protect high-risk populations against HIV/HCV co-infection, such as health care workers and injection drug users.43,44

In conclusion, the present study provides an important proof of concept for the therapeutic potential of AvFc against HCV infection via targeting envelope HMGs. In particular, the lectibody may provide a safe and efficacious means to prevent recurrent infection on liver transplantation in HCV-related end-stage liver disease patients. Other potential utilities of AvFc may be found in pre-exposure prophylaxis against HIV/HCV co-infection in
high-risk populations, as well as in the context of transplantation of organs from HCV-infected donors to HCV-negative recipients, which may help alleviate the severe shortage of donor organs available for transplantation. Further studies are warranted to determine a dose-response relationship, therapeutic window, and feasibility of intravenous or subcutaneous dosing routes, as well as to assess the efficacy of AvFc against established infection.

**Materials and Methods**

**Animal Care**

The use of animals was approved by the University of Louisville’s Institutional Animal Care and Use Committee and the Animal Ethics Committee of PhoenixBio Company, Ltd (resolution 2281). All animals were given a standard diet and water ad libitum and were housed in a temperature- and humidity-controlled facility with a 12-hour day/night cycle.

**Table 3. Histopathology of Chimeric Mouse Liver Tissue**

|                | Vehicle | AvFc (25 mg/kg), 11 doses | AvFc<sup>lec</sup> (25 mg/kg), 11 doses | AvFc, 11 doses | AvFc, 8 doses |
|----------------|---------|--------------------------|----------------------------------------|---------------|--------------|
| Mouse hepatocytes | 0       | 0                        | 0                                      | 0             | 0            |
| Human hepatocytes |         |                          | 2                                      | 3             | 3            |
| Fatty change, macrovesicular | 3       | 3                        | 3                                      | 3             | 3            |
| Infiltrate, inflammatory cell, around vacuolated hepatocyte | 0       | 0                        | 0                                      | 0             | 0            |
| Portal canal and others |         |                          | 0                                      | 0             | 0            |
| Hepatocellular carcinoma, trabecular, with extramedullary hematopoiesis | P       | 0                        | 0                                      | 0             | 0            |
| Metaplasia, osseous | 0       | 0                        | 0                                      | 0             | 0            |
| Pigmentation, brown, histiocyte, Glisson sheath, focal | 0       | 0                        | 0                                      | 0             | 0            |

*NOTE. Numbers shown are the severity score on a scale of 0–5. P, present.*
Figure 7. Histopathologic examination of PXB mouse liver tissues. Representative H&E-stained liver tissue section images corresponding to histopathologic findings in Table 2 are shown. Liver tissues are from the toxicologic study in Figure 4. (A) A 4x image from an animal in the vehicle control group (mouse ID: 103 in Table 2) showing low magnification of vacuolated hepatocytes. (B) A 10x image from a portion of panel A, containing many human hepatocytes with a large, well-defined, rounded vacuole. (C) Higher magnification (40x) of panel B. (D) A 10x image from an animal in the AvFc group (ID: 202 in Table 2), showing small foci of inflammatory cell infiltration in the human hepatocyte area. (E) Higher magnification (40x) of panel D. Inflammatory cells appear to surround vacuolated hepatocytes. (F) A 20x image from an animal in the AvFc group (8 total doses; ID: 401 in Table 2). Histiocytic brown pigmentation in the Glisson sheath was noted only in this mouse.

Production of AvFc and Non–HMG-Binding AvFc Variant

AvFc and AvFc<sub>lec</sub> were produced by agroinfiltration with magnICON vectors in Nicotiana benthamiana plants as previously described.54 AvFc was purified from plants after a 7-day incubation period using protein A and ceramic hydroxyapatite chromatography.

HCV Neutralization Assays

Huh-7 cells<sup>47</sup> and HEK-293T cells (American Type Culture Collection, Manassas, VA) were cultured in Dulbecco’s modified Eagle medium supplemented with 10% heat-inactivated fetal calf serum and 1% penicillin/streptomycin. To produce HCVcc, we used a modified version of the plasmid encoding JFH1 genome (genotype 2a), provided by T. Wakita (National Institute of Infectious Diseases, Tokyo, Japan).<sup>48,49</sup> The H77/JFH1 chimera, which expresses the core-NS2 segment of the genotype 1a polyprotein within a genotype 2a background, has been described previously.<sup>50</sup> The genotype 4a ED43/JFH1<sup>51</sup> genotype 5a SA13/JFH1<sup>52</sup> and genotype 6a HK6a/JFH1<sup>53</sup> infectious HCV recombinants were provided by J. Bukh (University of Copenhagen, Copenhagen, Denmark). Retroviral pseudotypes bearing HCV envelope glycoproteins of JFH1 virus (HCVpp) expressing the Firefly luciferase reporter gene were produced in HEK-293T as previously described.<sup>54</sup> Inhibitory effects were determined by quantifying infectivity by indirect immunofluorescence with the anti-E1 monoclonal antibody A4<sup>55</sup> or an anti-NS5A polyclonal antibody kindly provided by M. Harris (University of Leeds, Leeds, UK).

Formulation Buffer Optimization

Initial buffer screening was performed in 30 mmol/L glutamate, acetate, citrate, succinate, histidine, and phosphate buffers at pH 4.5–7.5 (Table 2). All the buffer agents were purchased from MilliporeSigma. AvFc was dialyzed and adjusted to 1 mg/mL (or 62.5 μg/mL) in respective buffers. Stability was evaluated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis after incubation for 2 weeks at 37°C. The melting temperatures of AvFc were determined by differential scanning fluorimetry performed on an Applied Biosystems StepOnePlus reverse-transcription polymerase chain reaction (RT-PCR) system as described previously.<sup>54</sup> Briefly, AvFc formulated in various buffers at a concentration of 50 μmol/L was mixed with a final concentration of 50x SYPRO Orange (S6651; ThermoFisher Scientific) in a 96-well template. The melting temperature was determined by the vertex of the first derivative of the relative fluorescence unit values in the melt curves. AvFc formulated into the optimized histidine buffer or PBS then was concentrated to 10 mg/mL and incubated.
at 4°C or room temperature. Absorbance at 280 nm and 600 nm was measured immediately after concentration and then again after 16 and 72 hours. A_{280} was measured after centrifugation of precipitate.

**Pharmacokinetic Analysis**

A pharmacokinetic profile for AvFc was generated after a single 25-mg/kg intraperitoneal injection in C57bl/6 mice (The Jackson Laboratory, Bar Harbor, ME) (8-week-old males and females; n = 4 per time point) and sampling blood at 0.5, 1, 2, 4, 8, 12, 24, and 48 hours after injection. The concentration of AvFc then was measured using an HIV gp120-coated enzyme-linked immunosorbent assay. Briefly, a recombinant gp120 (HIV CM235; AIDS Reagent Program; National Institutes of Health, Bethesda, MD) was coated overnight at 0.3 μg/mL followed by blocking with 5% dry milk-PBST. Serum samples at varying dilutions were incubated for 2 hours, followed by detection by a goat anti-human Fc–horseradish-peroxidase secondary antibody (ThermoFisher Scientific). The plasma concentration of AvFc was calculated by interpolating from a standard curve. PK parameters were calculated using the PKSolver Microsoft Excel add-on.

Figure 8. The protective effect of AvFc against HCV challenge in PXB mice. (A) Study design. PXB mice were challenged intraperitoneally with a HCV genotype 1a virus on day 0, simultaneously with an initial treatment intraperitoneally with either 25 mg/kg of AvFc or AvFc^lec^ (n = 5 each). The general conditions and body weights of the animals were monitored every other day, while serum HCV RNA and blood h-Alb levels were measured every 7 days. (B) Serum HCV RNA levels. AvFc treatment (both 8 and 11 doses) showed no detectable HCV RNA at any time point. The gray line indicates the lower limit of quantification, which was 4 \times 10^4 copies/mL in this assay. **P < .01, ***P < .001 (AvFc^lec^ vs both AvFc 8 and 11 doses); 2-way analysis of variance with the Tukey multiple comparison test. Inset: The graph shows the same data with the y-axis on a linear scale. (C–E) Time course of body weight change from day 0 (C), blood h-Alb levels (D), and serum h-Alt concentrations (E). Each data point represents means ± SEM in each group. *P < .05 (C, AvFc^lec^ vs AvFc 8 doses; D, AvFc^lec^ vs AvFc 11 doses; 2-way analysis of variance with the Tukey multiple comparison test. (E) No significant difference between groups at any time point was noted.
Toxicologic Analysis and HCV Challenge Study in PXB Mice

The mouse model of toxicologic analysis and HCV infection and toxicologic analysis was performed in PXB mice (complementary DNA–uPA<sup>wild</sup>/–/SCID, complementary DNA–uPA<sup>wild</sup>/–/; B6; 129SvEv-Plau, SCID: CB-17/1cr- scid/scid Jc); reviewed by Tateno and Kojima<sup>2</sup>). These mice contain transplanted human hepatocytes with a replacement index of greater than 70% as determined by blood h-Alb measurements before virus inoculation.<sup>2</sup> Blood h-Alb levels indicate the level and integrity of human hepatocyte engraftment in the mouse liver. Mice were separated into the following 3 treatment groups: AvFc<sup>lec</sup> (25 mg/kg, n = 5) for 11 doses, or AvFc (25 mg/kg, n = 5 each) for 8 or 11 doses. The initial treatment was co-administered intraperitoneally with virus inoculation (5 × 10<sup>5</sup> copies/kg) on day 0 with a genotype 1a strain (PBC002), and treatment continued every other day thereafter. The general conditions and body weights of the animals were monitored every other day, while serum HCV RNA and blood h-Alb were measured every 7 days by RT-PCR or latex agglutination immunonephelometry (LZ Test Eiken U-Alb; Eiken Chemical Co, Ltd), respectively. The HCV RNA RT-PCR assay was developed based on the method described by Takeuchi et al<sup>45</sup> with modifications, and validated by PhoenixBio for use in this animal model. The lower limit of quantification was determined to be 4.0 × 10<sup>4</sup> copies/mL. Serum ALT levels were determined either using a Fujifilm DRI-CHEM NX500sV clinical chemistry instrument or by enzyme-linked immunosorbent assay (Institute of Immunology Co, Ltd, Tokyo, Japan). At study termination on day 35, animals were killed and subject to gross necropsy and general health. Blood also was drawn via cardiac puncture and used for ALT, HCV RNA, and h-Alb analyses.

Histopathologic Analysis of Liver Tissues

H&E-stained liver sections from 3 to 4 mice per group were generated by Nara Pathology Research Institute Co, Ltd (Nara, Japan) and evaluated by pathologists at SkyPatho, LLC. All slides were examined by a blinded, board-certified veterinary pathologist under a light microscope (BX43; Olympus Corporation, Tokyo, Japan). The tissues were assigned a severity score for a number of characteristics based on the 5-point scoring system of the CDISC SEND Controlled Terminology, as follows: 0, unremarkable; 1, minimal; 2, mild; 3, moderate; 4, marked; 5, severe; and P, present.

Statistical Analyses and Data Analysis

Statistical significance was analyzed by GraphPad Prism 6 software (La Jolla, CA). Mouse body weights, albumin, ALT, and HCV RNA levels were compared using a repeated-measures 2-way analysis of variance with the Geisser–Greenhouse correction. Multiple comparisons between groups at each time point were conducted and corrected using the Tukey method with the threshold of significance set at P = .05. Liver:body-weight ratios were compared using 1-way analysis of variance. All authors had access to the study data, and reviewed and approved the final manuscript.

References

1. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004;39:5–19.
2. Blach S, Zeuzem S, Manns M, Altraif I, Dubeck A-S, Muljono DH, Waked I, Alavian SM, Lee M-H, Negro F. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161–176.
3. Zibbell JE, Asher AK, Patel RC, Kupronis B, Iqbal K, Ward JW, Holtzman D. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health 2018;108:175–181.
4. Zibbell JE, Iqbal K, Patel RC, Surayprasad A, Sanders KJ, Moore-Moravian L, Serreccchia J, Blankenship S, Ward JW, Holtzman D. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤ 30 years—Kentucky, Tennessee, Virgina, and West Virginia, 2006–2012. MMWR Morb Mortal Wkly Rep 2015;64:453.
5. Manns MP, Buti M, Gane E, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 2015;149:1345–1360.
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindoller R, Goodman ZD, Koury K, Ling M-H, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–965.
7. Jacobson IM, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindoller R, Goodman ZD, Koury K, Ling M-H, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–965.
8. Jacobson IM, McHutchison JG, Buschko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Bzowej NH, Marcellin P. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 2015;149:1345–1360.
9. Jacobson IM, McHutchison JG, Buschko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Bzowej NH, Marcellin P. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 2015;149:1345–1360.
10. Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassannein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhassh M, Kort J, Liu R, Ng T, Krishnan P, Lin C-W, Mensa FJ. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol 2018;16:417–426.
11. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Piot M, Romero-Gomez M, Zarski J-P, Agarwal K, Buggisch P. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889–1898.
12. Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, Elkhashab M, Bernstein DE, Younes Z, Reindollar RW. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol 2016;64:301–307.

13. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ari ZB, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen B-Y. Grazoprevir–elbasvir combination therapy for treatment-naïve cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015;163:1–13.

14. Fernández-Carrillo C, Lemos S, Llop E, Pascasio JM, Fernández I, Ballellas C, Crespo J, Buti M, Castells L, Romero-Gómez M, Pons C, Moreno JM, Albillos A, Fernández-Rodríguez C, Prieto M, Fernández-Bermejo M, García-Samaniego J, Carrón JA, de la Mata M, Badia E, Salmerón J, Herreros JI, Salcedo M, Moreno JJ, Tumes J, Granados R, Blé M, Calleja JL. Treatment of hepatitis C virus in patients with advanced cirrhosis: always justified? Analysis of the Hepa-C Registry. J Hepatol 2016;64:S133.

15. Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub S-R, Martini S, Morelli C, Donato F, Volpes R, Pageaux G-P. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol 2016;65:524–531.

16. Jothimani D, Govil S, Rela M. Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review. Hepatol Int 2016;10:749–761.

17. Hughes MG Jr, Tucker WW, Reddy S, Brier ME, Koch D, McClain CJ, Jonsson CB, Matoba N, Chung D. Rate of hepatitis C viral clearance by human livers in non-human patients: liver transplantation modeling primary infection and implications for studying entry inhibition. PLoS One 2017;12:e0180719.

18. Femmuto DJ, Coilly A, Chung RT, Samuel D, Baumer TF. New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect Dis 2016;16:735–745.

19. Colpitts CC, Baumert TF. Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals. Hepatol Int 2016;10:741–748.

20. Jacob RE, Perdivara I, Przybylinski M, Tomer KB. Mass spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycans. J Am Soc Mass Spectrom 2008;19:428–444.

21. Walls AC, Tortorici MA, Frenz B, Snijder J, Li W, Rey FA, DiMaio F, Bosch B-J, Veesler D. Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. Nat Struct Mol Biol 2016;23:899–905.

22. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990;265:10373–10382.

23. Suga A, Nagae M, Yamaguchi Y. Analysis of protein landscapes around N-glycosylation sites from the PDB repository for understanding the structural basis of N-glycoprotein processing and maturation. Glycobio 2018;28:774–785.

24. Hamorsky KT, Koukam JC, Dent MW, Grooms TN, Husk AS, Hume SD, Rogers KA, Villinger F, Morris MK, Hanson CV, Matoba N. Engineering of a lectibody targeting high-mannose-type glycans of the HIV envelope. Mol Ther 2019;27:2038–2052.

25. Tateno C, Kojima Y. Characterization and applications of chimeric mice with humanized livers for preclinical drug development. Lab Anim Res 2020;36:2.

26. Hamorsky KT, Grooms-Williams TW, Husk AS, Bennett LJ, Palmer KE, Matoba N. Efficient single toba-moviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides. Antimicrob Agents Chemother 2013;57:2076–2086.

27. Goffard A, Callens N, Bartsch B, Wychowski C, Cosset F-L, Montpellier C, Dubuisson J. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol 2005;79:8400–8409.

28. Meuleman P, Albecka A, Belouzard S, Vercauteren K, Verhoye L, Wychowski C, Leroux-Roels G, Palmer KE, Dubuisson J. Griffithsin has antiviral activity against hepatitis C virus. Antimicrob Agents Chemother 2011;55:5159–5167.

29. Helle F, Wychowski C, Vu-Dac N, Gustafson KR, Voisset C, Dubuisson J. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycosylated. J Biol Chem 2006;281:25177–25183.

30. Hoque MM, Suzuki K, Tsunoda M, Jiang J, Zhang F, Takahashi A, Ohbayashi N, Zhang X, Tanaka H, Omura S, Takénaka A. Structural insights into the specific anti-HIV property of actinohivin: structure of its complex with the α-1(2)-mannonbiose moiety of gp120. Acta Crystallogr D Biol Crystallogr 2012;68:1671–1679.

31. Freedman H, Logan MR, Hockman D, Koehler Leman J, Cholankeril G, Ahmed A. Alcoholic liver disease replaces viral hepatitis C virus as the leading indication for liver transplantation in the United States. Clin Gastroenterol Hepatol 2013;57:2076–2086.

32. Colpitts CC, Chung RT, Baumert TF. Entry inhibitors: a perspective for prevention of hepatitis C virus infection in organ transplantation. ACS Infect Dis 2017;3:620–623.

33. Baumert TF, Jühling F, Ono A, Hoshida Y. Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med 2017;15:52.

34. Colpitts CC, Baumert TF. Addressing the challenges of hepatitis C virus resistance and treatment failure. Multidisciplinary Digital Publishing Institute, 2016.
37. Colpitts CC, Tsai PL, Zeisel MB. Hepatitis C virus entry: an intriguingly complex and highly regulated process. Int J Mol Sci 2020;21:2091.

38. Terraut N, Shrestha R, Satapathy SK, O’Leary JG, Campsen J, Rosenau J, Spivey J, Teperman LW, Thao P, Vema EC, Vierling JM, Schiano TD, Sher L, Khallafi H, Victor D, Bhamidimarri KR, Gordon FD, Hanish S, Kulik LM, Lake-Bakagaar G, Maluf D, Porayko M, Bramer SL, Osgood G, Chavan S, Daeleen N. LP17: Novel approach for the prevention of recurrent hepatitis C in liver transplant recipients: preliminary results from ongoing phase III trial with cirivir. J Hepatol 2015;62:S271–S272.

39. Smith HL, Chung RT, Mantry P, Chapman W, Curry MP, Schiano TD, Boucher E, Cheson DC, Wang Y, Molrine DC. Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: a proof-of-concept study. J Viral Hepat 2017;24:197–206.

40. Helle F, Goffard A, Morel V, Duverlie G, Meckating J, Keck Z-Y, Fourg S, Penin F, Dubuisson J, Voisset C. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol 2007;81:8101–8111.

41. Pantua H, Diao J, Ultsch M, Hazen M, Mathieu M, McCutcheon K, Takeda K, Date S, Cheung TK, Phung Q. Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies. J Mol Biol 2013;425:1899–1914.

42. Balzarini J. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat Rev Microbiol 2007;5:583–597.

43. Peters L, Klein MB. Epidemiology of hepatitis C virus in HIV-infected patients. Curr Opin HIV AIDS 2015;10:297–302.

44. Schrann AJ, Barrett J, Hurt CB, Malvestutto C, Miller WC. Challenges facing a rural opioid epidemic: treatment and prevention of HIV and hepatitis C. Curr HIV/AIDS Rep 2018;15:245–254.

45. Ruck JM, Segev DL. Expanding deceased donor kidney transplantation: medical risk, infectious risk, hepatitis C virus, and HIV. Curr Opin Nephrol Hypertens 2018;27:445–453.

46. Bodzin AS, Baker TB. Liver transplantation today: where we are now and where we are going. Liver Transpl 2018;24:1470–1475.

47. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res 1982;42:3856–3863.

48. Wakita T, Pietzschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich H-G, Mizokami M. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791.

49. Goueslain L, Alsaleh K, Horellou P, Roinegard P, Descamps V, Duverlie G, Cicizora Y, Wychowski C, Dubuisson J, Rouillé Y. Identification of GFB1 as a cellular factor required for hepatitis C virus RNA replication. J Virol 2010;84:773–787.

50. Maurin G, Fresquet J, Granio O, Wychowski C, Cosset F-L, Lavillette D. Identification of interactions in the E1E2 heterodimer of hepatitis C virus important for cell entry. J Virol Clin Biol 2011;286:23865–23876.

51. Scheel TK, Gottwein JM, Jensen TB, Prentoe JC, Hoehn AM, Alter HJ, Eugen-Olsen J, Bukh J. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc Natl Acad Sci USA 2008;105:997–1002.

52. Jensen TB, Gottwein JM, Scheel TK, Hoehm AG, Eugen-Olsen J, Bukh J. Highly efficient JFH1-based cell culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection. J Infect Dis 2008;198:1756–1765.

53. Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, Hoehm AG, Bukh J. Development and characterization of hepatitis C virus genotype 1–7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009;49:364–377.

54. De Beeck AO, Voisset C, Bartosch B, Cicizora Y, Cocquerel L, Keck Z, Fourg S, Cosset F-L, Dubuisson J. Characterization of functional hepatitis C virus envelope glycoproteins. J Virol 2004;78:2994–3002.

55. Dubuisson J, Hsu HH, Cheung RC, Greenberg HB, Russell DG, Rice CM. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol 1994;68:6147–6160.

56. Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 2010;99:306–314.

57. Ji C, Liu Y, Pamulapati C, Bohini S, Fertig G, Schraeml M, Rubas W, Brandt M, Ries S, Ma H, Klumpp K. Prevention of hepatitis C virus infection and spread in human liver chimeric mice by an anti-CD81 monoclonal antibody. Hepatology 2015;61:1136–1144.

58. Takeuchi T, Katsume A, Tanaka T, Abe A, Inoue K, Tsukiyama-Kohara K, Kawaguchi R, Tanaka S, Kohara M. Real-time detection system for quantification of hepatitis C virus genome. Gastroenterology 1999;116:636–642.
Supporting); Yoshinari Miyata (Data curation: Supporting; Formal analysis: Supporting; Investigation: Supporting; Methodology: Supporting; Project administration: Supporting; Validation: Equal; Writing – review & editing: Supporting); Yoshi Morikawa (Investigation: Supporting; Project administration: Supporting; Supervision: Supporting; Validation: Supporting; Writing – review & editing: Supporting); Yoshio Morikawa (Investigation: Supporting; Project administration: Supporting; Supervision: Supporting; Validation: Supporting; Writing – review & editing: Supporting); Nobuyuki Matoba, PhD (Conceptualization: Lead; Data curation: Equal; Formal analysis: Supporting; Funding acquisition: Lead; Investigation: Lead; Methodology: Lead; Project administration: Lead; Supervision: Lead; Validation: Equal; Writing – original draft: Supporting; Writing – review & editing: Lead).

The authors thank Adeline Danneels, Lucie Fénéant, Czeslaw Wychowski, Lauren Moore, and Jessica Jurkiewicz for their experimental help. The authors also are grateful to R. Bartenschlager, J. Bukh, F.L. Cosset, M. Harris, and T. Wakita for providing essential reagents. The immunofluorescence analyses were performed with the help of the imaging core facility of the BioImaging Center Lille Nord-de-France.

Conflicts of interest
This author discloses the following: Nobuyuki Matoba is an inventor on a patent concerning the composition and utility of Avaren-Fc (US patent number 8802822). The remaining authors disclose no conflicts.

Funding
This work was supported by the University of Louisville ExCITE program, which was funded by US National Institutes of Health (U01 HL127518) and the Leona M. and Harry B. Helmsley Charitable Trust. Avaren-Fclec- was created from work supported by a National Institutes of Health grant (R33 AI088585).